Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era [Corrigendum]

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Corrigendum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360789/
https://www.ncbi.nlm.nih.gov/pubmed/25792842
http://dx.doi.org/10.2147/OTT.S80592
_version_ 1782361583849046016
collection PubMed
description
format Online
Article
Text
id pubmed-4360789
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-43607892015-03-19 Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era [Corrigendum] Onco Targets Ther Corrigendum Dove Medical Press 2015-03-09 /pmc/articles/PMC4360789/ /pubmed/25792842 http://dx.doi.org/10.2147/OTT.S80592 Text en © 2015 Berger et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Corrigendum
Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era [Corrigendum]
title Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era [Corrigendum]
title_full Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era [Corrigendum]
title_fullStr Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era [Corrigendum]
title_full_unstemmed Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era [Corrigendum]
title_short Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era [Corrigendum]
title_sort outcomes analysis of an alternative formulation of pegylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era [corrigendum]
topic Corrigendum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360789/
https://www.ncbi.nlm.nih.gov/pubmed/25792842
http://dx.doi.org/10.2147/OTT.S80592

Ejemplares similares